Figure 1. Metastatic liver lesions responded to olaparib and camrelizumab combination therapy (PARPi+ICI). (A) Diagram summarizing the various treatment modalities received by our patient. (B) Abdominal magnetic resonance imaging scans of the liver lesions before, during, and at clinical progression with PARPi+ICI therapy. (C-D) Longitudinal monitoring of serum levels of breast cancer-related tumor biomarkers CA125 and CA153 (C) and liver function biomarkers AST and GGT (D) from the start of PARPi+ICI therapy until disease progression.
PARPi = poly(ADP-ribose) polymerase inhibitors; ICI = immune checkpoint inhibitors; AST = aspartate aminotransferase; GGT = gamma-glutamyl transferase.